UMN Pharma Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 57

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $45.9M

  • Investors
  • 1

UMN Pharma General Information

Description

Developer of next-generation logical vaccines intended to meet the needs of unsatisfied medical fields. The company's development concept integrates the production technology of recombinant protein antigen, which is the drug substance of next-generation bio pharmacy, adjuvant technology, and formulation/drug delivery technology, thereby aiming at boosting immunity to enhance the vaccine's effectiveness that can be made available worldwide.

Contact Information

Website
www.umnpharma.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 7 Floor, Tekko Building, 1-8-2
  • Marunouchi, Chiyoda-ku
  • Tokyo, 100-0005
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Parent Company
Shionogi
Vertical(s)
Life Sciences
Corporate Office
  • 7 Floor, Tekko Building, 1-8-2
  • Marunouchi, Chiyoda-ku
  • Tokyo, 100-0005
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

UMN Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 12-Dec-2019 $45.9M Completed Generating Revenue
8. PIPE 16-Nov-2017 Completed Generating Revenue
7. PIPE 17-Oct-2013 Completed Generating Revenue
6. IPO 11-Dec-2012 Completed Generating Revenue
5. Later Stage VC (Series C) 21-Feb-2007 Completed Generating Revenue
4. Later Stage VC Completed Generating Revenue
3. Early Stage VC (Series B2) 03-Feb-2006 Completed Startup
2. Early Stage VC (Series B1) 17-Oct-2005 $1.1M $2M Completed Startup
1. Early Stage VC (Series A) 31-Dec-2004 $900K $900K Completed Startup
To view UMN Pharma’s complete valuation and funding history, request access »

UMN Pharma Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 9

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

UMN Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-6704074-B2 Method for purifying virus-like particles Active 04-Feb-2019
JP-2019110904-A Purification method of virus-like particles Active 04-Feb-2019
JP-2015015931-A Method for producing culture comprising virus-like particles Pending 12-Jul-2013
JP-2015017065-A Pharmaceutical composition comprising norovirus virus-like particles Pending 12-Jul-2013
WO-2015004995-A1 Pharmaceutical composition containing virus-like particles of norovirus Inactive 12-Jul-2013 A61K39/12
To view UMN Pharma’s complete patent history, request access »

UMN Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

UMN Pharma Former Investors (27)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ant Capital Partners PE/Buyout Minority
Api Co Corporation Minority
Astellas Pharma Corporation Minority
Collabo Sangakukan Corporation Minority
Cybird Corporation Minority
You’re viewing 5 of 27 investors. Get the full list »

Ready to get started?

Request a free trial

UMN Pharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view UMN Pharma’s complete esg history, request access »

UMN Pharma FAQs

  • When was UMN Pharma founded?

    UMN Pharma was founded in 2004.

  • Where is UMN Pharma headquartered?

    UMN Pharma is headquartered in Tokyo, Japan.

  • What is the size of UMN Pharma?

    UMN Pharma has 57 total employees.

  • What industry is UMN Pharma in?

    UMN Pharma’s primary industry is Drug Discovery.

  • Is UMN Pharma a private or public company?

    UMN Pharma is a Private company.

  • What is the current valuation of UMN Pharma?

    The current valuation of UMN Pharma is .

  • What is UMN Pharma’s current revenue?

    The current revenue for UMN Pharma is .

  • How much funding has UMN Pharma raised over time?

    UMN Pharma has raised $88.4M.

  • Who are UMN Pharma’s investors?

    Ant Capital Partners, Api Co, Astellas Pharma, Collabo Sangakukan, and Cybird are 5 of 27 investors who have invested in UMN Pharma.

  • When was UMN Pharma acquired?

    UMN Pharma was acquired on 12-Dec-2019.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process